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Abstract
Background: Treatment of postmenopausal, hormone receptor-positive metastatic breast cancer (MBC) patients
varies despite clear therapy guidelines, favoring endocrine treatment (ET). Aim of this study was to analyze
persistence of palliative aromatase inhibitor (AI) monotherapy in MBC patients.
Methods: EvAluate-TM is a prospective, multicenter, noninterventional study to evaluate treatment with letrozole in
postmenopausal women with hormone receptor–positive breast cancer. To assess therapy persistence, defined as
the time from therapy start to the end of the therapy (TTEOT), two pre-specified study visits took place after 6 and
12 months. Competing risk survival analyses were performed to identify patient and tumor characteristics that
predict TTEOT.
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Results: Out of 200 patients, 66 patients terminated treatment prematurely, 26 (13%) of them due to causes other
than disease progression. Persistence rate for reasons other than progression at 12 months was 77.7%. Persistence
was lower in patients who reported any adverse event (AE) in the first 30 days of ET (89.5% with no AE and 56%
with AE). Furthermore, patients had a lower persistence if they reported compliance problems in the past before
letrozole treatment.
Conclusions: Despite suffering from a life-threatening disease, AEs of an AI will result in a relevant number of
treatment terminations that are not related to progression. Some subgroups of patients have very low persistence
rates. Especially with regard to novel endocrine combination therapies, these data imply that some groups of
patients will need special attention to guide them through the therapy process.
Trial registration: Clinical Trials Number: CFEM345DDE19
Keywords: Advanced/metastatic breast cancer, Palliative/metastatic treatment, Compliance, Persistence, Endocrine
treatment/therapy, Aromatase inhibitor
Background
Endocrine therapy (ET) is the recommended treatment
in patients with hormone receptor-positive, advanced
breast cancer. While, according to current guidelines,
premenopausal women should receive tamoxifen as
first-line therapy, aromatase inhibitors (AIs) or fulves-
trant are preferred in postmenopausal metastatic breast
cancer (MBC) patients [1, 2].
ET has recently become the focus of MBC treatment
as novel combination therapies are being developed for
hormone receptor-positive, advanced breast cancer pa-
tients to overcome endocrine resistance [3]. Adding the
mTOR inhibitor everolimus to a therapy with the AI
exemestane, for instance, improved progression-free sur-
vival (PFS) [4]. Furthermore, a combination of the
cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors palbo-
ciclib, ribociclib, or abemaciclib with ET has been inves-
tigated and has consistently shown a clinically relevant
improvement in PFS [5–7].
To ensure ET efficacy, patient compliance and treat-
ment persistence are needed in both the adjuvant and ad-
vanced setting. In the adjuvant setting, which has been
investigated in several trials, compliance and persistence
of therapy with tamoxifen or AIs in postmenopausal
breast cancer patients decrease over the course of treat-
ment [8–11], which, in turn, is associated with reduced
disease-free survival (DFS) [12]. Some baseline patient and
tumor characteristics such as age, socioeconomic factors,
or tumor stage have been reported to have an influence
[8–14]. In the advanced setting, in contrast, only few stud-
ies have analyzed patient compliance with ET, and thus
not much is known about possible risk factors [15, 16].
Data concerning the persistence with regard to AI might
not only be helpful for patients treated with a monother-
apy but also for comparing persistence regarding endo-
crine combination therapies. Aim of this study was,
therefore, to describe therapy persistence and to identify
predictors for therapy persistence among those patient
and tumor characteristics known at the start of treatment
in a prospective, noninterventional study in patients re-
ceiving letrozole monotherapy in the metastatic setting.
The hypothesis was that side effects and patient character-
istics result in patients with different adherence rates.
Methods
Patients
EvAluate-TM is a prospective, multicenter, noninterven-
tional, and observational study that evaluated treatment
with the AI letrozole in postmenopausal hormone
receptor-positive breast cancer patients in Germany [14,
17–19]. According to drug approval guidelines, patients
received letrozole at 2.5 mg per day and were allowed to
be on treatment up to 30 days before and required to
start at maximum 30 days after signing informed con-
sent. Follow-up took place for 12 months, while the last
visit was allowed to be performed up to 3 months later.
Besides, a minimum follow-up of 30 days was required
for AE-analysis. Other inclusion or exclusion criteria
were not defined. All patients provided written informed
consent and all respective ethics committees approved
the study.
Data acquisition
Data on patient and tumor characteristics, including
epidemiological characteristics, comorbidities, concomi-
tant medication, as well as tumor stage and previous
therapies, were entered into electronic case report forms.
Patients were observed up to 15months. At two prespe-
cified study visits after 6 and 12 months from study
inclusion, information about therapy compliance and
whether the therapy had been stopped since the last visit
was gathered from both patients and physicians. If the
therapy had ended, the reason and date had to be docu-
mented. Furthermore, physicians and patients completed
prespecified questionnaires about therapy compliance.
Patients’ general health status and information on the
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perception of educational content provided on AI
treatment was assessed.
End points
The time from therapy start to the end of the therapy
(TTEOT) was defined as therapy persistence. In the
literature, terminology for describing compliance and
persistence with therapy varies [12, 20, 21]. According to
the current terminology, the treatment period is defined
by the term persistence [20]. To simplify the discussion
of study results, the term adherence is used as an
overarching term for compliance and persistence in this
analysis, which is in line with other studies [12, 22]. A
patient was censored at the maximum observation time
of 15 months according to the study plan or before, as
the case may be, at the date of progression or death. The
study aimed to evaluate the factors influencing the
therapy decision of both the physician and the patient in
standard care and assess patient management of therapy.
Statistical methods
Patient population and patient characteristics were
described with means, standard deviations (continuous
variables), or absolute and relative frequencies (ordinal
or dichotomous variables). As the trial was designed as
an explorative study, all the p-values presented should
be considered descriptive values.
Two competing risk survival analyses were performed
to identify patient and tumor characteristics and items of
the prespecified questionnaires that predict TTEOT. The
competing risk was determined as the end of therapy due
to disease progression and the end of therapy for reasons
other than disease progression was determined as the
event. The variables included in the analyses were selected
due to their possible influence in parallel with a univariate
analysis of the possible influencing factors (not reported).
The first competing risk-survival analysis was based on
patient and tumor characteristics as predictors of TTEOT,
including the variables age at therapy begin (continuous),
body mass index (continuous), ECOG (dichotomous, 0–1
and 2–4), number of different concomitant medications
(integer), time from diagnosis to therapy (continuous),
and adverse events (AE) in the first 30 days (dichotomous)
. The second competing risk-survival analysis considered
the following items from the prespecified questionnaire
(asked before beginning treatment with letrozole) as pos-
sible predictors of TTEOT: Do you sometimes forget to
take your medicine? (yes/no); Do you take all your medi-
cine always at the same time? (yes/no); Do you sometimes
not take your medicine if you feel good? (yes/no); Do you
not take your medicine at all if you feel worse due to
illness? (yes/no); On how many days in the past 30 days
did you not take/forget to take your medicine? (number of
days); How satisfied were you with the information
provided regarding endocrine treatment and its side
effects? (from very satisfied to very unsatisfied on a scale
of 1–5).
All statistical calculations were performed with the
package RiskRegression of the statistics software R
Version 3.4.1 and with the software SPSS Version 24.
Results
Between 01/2008 and 12/2009 a total of 5045 patients
were enrolled in the study, of whom 252 had advanced
breast cancer. Of these, 52 women were excluded, out of
which 28 patients were excluded because endocrine
therapy started more than 30 days before signing the
informed consent and 14 patients because treatment was
started more than 30 days after the informed consent. In
4 patients the follow-up was too short (< 30 days) for
side effect evaluation and in 6 patients data on disease
progression or therapy compliance was missing. Thus,
the current analysis consists of data of 200 MBC
patients (Additional file 1: Figure S1).
Patient characteristics
On average, the patients were 66.2 years old (SD = 11.3)
and had a body mass index of 27.3 (SD = 5.4) kg/m2. Of
the patients 60.0% had a pT2-T4 tumor and 56.0% had
MBC at first diagnosis. Further patient and tumor
characteristics are described in Table 1.
The median observation time was 10.6 (SD = 3.9)
months. A total of 66 (33.3%) therapy terminations were
observed, of which 26 (13.0%) were for reasons other
than disease progression or death.
The main nonprogression-related reason for premature
treatment termination, which was reported at the time of
treatment discontinuation, was side effects. Side effects
were reported in 19 of the 26 events (9.5%). In one case
(0.5%) therapy was discontinued due to the patient’s wish
and in six cases (3.0%) for other reasons.
Persistence rate for patients with no progression
during the observation time was 85.5% at month 12.
Prediction of persistence
Descriptive statistics for the possible predictors for non-
persistence for reasons other than disease progression can
be found in Table 2. The results of the two competing
risk-survival analyses are shown in Table 3. In the first
model the predictor “adverse events in the first 30 days”
showed a significant p-value of p < 0.0001, indicating a
possible influence on TTEOT. Hazard ratio (HR) was 8.24
(95% CI: 3.02–22.49) for patients with an AE compared to
patients without. No other variable showed any significant
influence on patients’ persistence in this model.
In the second model, the patients’ statements before
therapy begin concerning treatment compliance in the past
to any medication were tested. Their statement that they
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tend to “not taking medication if feeling ill” and the stated
number of days patients were noncompliant with their
concomitant medication over the previous 30 days showed
a possible influence as predictors of TTEOT with p-values
of p < 0.01. Patients who stated previous noncompliance if
feeling ill had a higher risk for therapy termination than
women who took their medication continuously (HR =
4.00; 95% CI: 1.89–8.44). Women who did not take their
concomitant medication for at least 1 day also showed a
higher risk for a lower persistence rate at 12months with a
HR of 2.79 (95% CI: 1.30–6.00).
Kaplan–Meier curves for possible predictors of persist-
ence are shown in Fig. 1. Estimates for persistence rates
at 12 months were 89.5 and 56.0% for patients without
and with AEs, respectively. Persistence rates for patients,
who stated they stopped therapy if feeling ill vs. those
who did not state that, were 85.7 and 86.0%, respectively.
With regard to women who did not take their concomi-
tant medication for at least 1 day, the 12-month persist-
ence rate was 72.7% compared with those who never
missed taking their medication (86.9%).
Discussion
After 12 months of observation, patients who were non-
persistent for reasons other than disease progression
were still under AI treatment, with a persistence rate of
85.5%. In these patients, persistence was clearly compro-
mised when AEs were reported within the first 30 days
of treatment. Furthermore, statements about noncompli-
ance in the past could also predict lower persistence.
ET with an AI not only reduces the recurrence rate of
hormone receptor-positive breast cancer in the adjuvant
setting [23], it also prolongs overall survival (OS) in
those patients with advanced breast cancer [24]. As in
the adjuvant setting adherence to AI therapy seems to
have a direct influence on DFS [12], an important role in
the treatment of MBC can be hypothesized.
In early breast cancer age [9, 13], comorbidities [9],
prior chemotherapy or radiation [25, 26], tumor size
[13], as well as socioeconomic factors [25] have been
reported to have an influence on adherence to ET. In a
Brazilian cohort of breast cancer patients, those who
were diagnosed at a noncurable stage were less adherent
to ET [25], while other contradictory analyses report
that the stage at diagnosis seems to be associated with
persistence, but not compliance [27]. Among MBC
patients, there are only few analyses of adherence to ET
[15, 16, 28]. An Italian investigator group observed
among 285 postmenopausal MBC patients treated with
exemestane that those who were married or had a
university degree were less likely to not adhere to ET.
Furthermore, older age at diagnosis, a higher number of
comorbidities, as well as a lower receptivity toward
therapy seemed to be associated with nonadherence.
After 6 months of treatment, the adherence rate was
78% [15]. A recent analysis from Switzerland shows that
out of 165 women who started palliative ET, a total of
12.8% did not persist (therapy termination or therapy
change) with therapy due to side effects or for reasons
other than disease progression. Those who were naïve to
ET showed a higher persistence with palliative ET, while
those with more metastatic lesions at diagnosis were less
persistent [16]. In the FALCON study, 78.9% of the post-
menopausal MBC patients receiving anastrozole discon-
tinued treatment, among whom only 10.8% were for
Table 1 Patient and tumor characteristics
Characteristics mean or N SD or %
Age (in years) 66.2 11.32
BMI (kg/m2) 27.3 5.40
ECOG at study entry
0 81 40.5
1 93 46.5
2 20 10.0
3 5 2.5
4 1 0.5
pT at first diagnosis
Unknown 13 6.5
pT0-pT1 67 33.5
pT2-pT4 120 60.0
pN at first diagnosis
Unknown 42 21.0
pN0 58 29.0
pN1–3 100 50.0
cM at first diagnosis
Unknown 4 2.0
cM0 84 42.0
cM1 112 56.0
Tumor grade at first diagnosis
Unknown 6 3.0
G1 11 5.5
G2 137 68,5
G3 46 23.0
HER2/neu
Unknown 26 13.0
Negative 147 73.5
Positive 27 13.5
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reasons other than disease progression. Of these treat-
ment terminations, 4.7% were reported to be due mainly
to adverse events. The median duration of actual expos-
ure to anastrozole was 13.9 months [28].
Some of the aforementioned patient and tumor charac-
teristics were also investigated in the present analysis.
While none of the analyzed patient characteristics such as
age, BMI, ECOG, or the number of concomitant medica-
tions had a significant influence on therapy persistence,
AEs in the early treatment phase and patient noncompli-
ance due to illness and forgetfulness correlate with nonper-
sistence. As mentioned before, literature on predictors of
persistence with palliative ET is scarce, and thus it is diffi-
cult to bring these results in line with others. AI-induced
side effects, which are described as the main reason for
nonpersistence in the present work, represent one reason
often given for noncompliance and an associated premature
end of treatment [26, 29]. In the adjuvant setting, the
Table 2 Possible predictors for patients nonpersistent for reasons other than disease progression
Possible Predictors Persistence Non-persistence
Mean or N SD or % Mean or N SD or %
Age (in years) 66.4 11.5 66.2 10.9
BMI (kg/m2) 27.6 5.7 27.6 4.8
Number of concomitant medications 2.1 3.2 1.7 2.3
ECOG
0 56 41.8 13 50.0
1 62 46.3 10 38.5
2 11 8.2 3 11.5
3 4 3.0 0 0.0
4 1 0.7 0 0.0
Time from diagnosis to therapy (in years) 3.1 4.7 2.9 4.5
Adverse events within the first 30 days
No 123 91.8 18 69.2
Yes 11 8.2 8 30.8
Do you sometimes forget to take your medicine?
No 115 90.5 22 91.7
Yes 12 9.5 2 8.3
Do you take all your medicine always at the same time?
No 11 8.7 2 8.3
Yes 115 91.3 22 91.7
Do you sometimes not take your medicine if you feel good?
No 115 92.7 23 95.8
Yes 9 7.3 1 4.2
Do you not take your medicine at all if you feel worse due to illness?
No 121 96.0 22 91.7
Yes 5 4.0 2 8.3
On how many days in the past 30 days did you not take/forget to take your medicine?
0 109 93.2 20 87.0
1–10 8 6.8 3 13.0
How satisfied were you with the information provided regarding endocrine treatment and its side effects?
Very satisfied 45 40.5 6 25.0
Satisfied 46 41.4 11 45.8
Neither satisfied nor unsatisfied 8 7.2 5 20.8
Unsatisfied 8 7.2 1 4.2
Very unsatisfied 2 1.8 1 4.2
Not applicable 2 1.8 0 0.0
Wallwiener et al. BMC Cancer          (2019) 19:611 Page 5 of 9
COMPAS trial could demonstrate that compliance with
AIs improves side effects, while noncompliant women were
more likely to experience a deterioration of AE and might
therefore discontinue treatment prematurely [30]. This
might explain the vicious circle and why, in the current
analysis, adverse events and noncompliance are in turn
associated with a higher risk for nonpersistence.
For novel combination therapies, compliance rates are
only available from prospectively randomized clinical tri-
als. In the PALOMA-2 study with a median follow-up
time of 23 months, an overall permanent discontinuation
of study treatment as a result of AEs was reported in 43
patients (9.7%) in the palbociclib–letrozole group and in
13 patients (5.9%) in the placebo–letrozole group [5]. In
the MONALEESA-2 study, at a median duration since
randomization of 15.3 months, discontinuation due to
AEs was reported in 87 patients (26.0%) in the ribociclib
group and in 146 (43.7%) in the placebo group [7].
These figures are lower than those from our data. How-
ever, in clinical trials, compliance is generally thought to
be higher for several reasons. Therefore, it will be im-
portant to observe real-world data that will capture this
figure for patients on these novel combination therapies.
However, it can be assumed that the rate will be lower
than the 85.5% persistence rate that we reported for
monotherapy.
A strength of this study is that, due to the nationwide
patient recruitment, a broad MBC patient population is
represented. Interesting is the high rate of MBC at first
diagnosis, namely, 56.0%, which in the literature is re-
ported to be only 5–10% [1], but is similar to the per-
centage in recent studies in that patient population [6].
Further trials report lower rates [4, 5, 7], which
nevertheless, in comparison to epidemiologically known
data, are high, so that the question arises as to whether
there is a general increase in MBC at first diagnosis or
whether this is based on a study selection bias. A weakness
of our analysis is that, due to the small number of events
(n = 26), the possible predictors for TTEOT were split into
two competing risk regression models to achieve conver-
gence and obtain robust results. Therefore, the results of
the two models must be interpreted carefully by taking
into account the separation of the predictors. A further
weakness of the study is that data regarding compliance
were collected by evaluating patient questionnaires and
physicians’ assessments only at the time of enrollment and
after 6 and 12months. Since the median observation time
in this study was only 10.6months, but the median PFS of
an ET with an AI is about 14.0months according to the
literature [28], it can be assumed that therapy persistence
would even continue to decrease over the following
months. As patients were not observed after the end of
treatment, it also remains unknown whether women non-
persistent to letrozole treatment switched to another ET
or were nonpersistent in general and discontinued therapy
altogether. Importantly it has also to be noted that for our
predictor women would have to be observed for 30 days
with regard to the occurrence of side effects. Our findings
can only be used for these women. For women who ter-
minate the therapy before that time our findings are not
applicable.
Conclusion
The analysis suggests that the presence of AEs and state-
ments about previous noncompliance can predict those
women who will terminate palliative therapy with an AI.
Table 3 Prediction of time to end of treatment (TTOT) in patients not progressing under letrozole
Possible predictors Hazard Ratio 95% Confidence
Interval
p-value
Lower
Bound
Upper
Bound
Competing
Risk
Regression
Model 1
Age (in years) 1.02 0.97 1.08 0.373
BMI (kg/m2) 1.02 0.94 1.11 0.563
Number of concomitant medications 0.63 0.33 1.19 0.155
ECOG 0.52 0.07 4,07 0.532
Time from diagnosis to therapy (in years) 0.96 0.84 1.10 0.565
Adverse events within the first 30 days 8.24 3.02 22.49 < 0.0001
Competing
Risk
Regression
Model 2
Do you sometimes forget to take your medicine? 0.81 0.20 3.24 0.762
Do you take all your medicine always at the same time? 1.15 0.23 5.68 0.864
Do you sometimes not take your medicine if you feel good? 0.72 0.26 1.96 0.523
Do you not take your medicine at all if you feel worse due to illness? 4.00 1.89 8.44 0.0003
On how many days in the past 30 days did you not take/forget to take your medicine? 2.79 1.30 6.00 0.008
How satisfied were you with the information provided regarding endocrine treatment and its
side effects?
0.84 0.18 3.86 0.818
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Despite suffering from a life-threatening disease and re-
ceiving a treatment that is generally considered as being
well tolerated and thus the treatment of choice, AEs of
an AI and a behavioral pattern related to noncompliance
will result in a significant proportion of patients who
prematurely terminate treatment. Therefore, further ana-
lyses are necessary to find predictive factors and identify
MBC patients who are at risk for early treatment discon-
tinuation and could benefit from supporting compliance
programs. For example that up to 44% of women with
side effects would terminate the therapy within 12
months of treatment compared to about 11% without
side effects, makes this population a group of patients of
interest who should be part of an intensified treatment
management program. Furthermore, it should be
investigated whether compliance and persistence pat-
terns are the same with novel endocrine combination
therapies.
Additional file
Additional file 1: Figure S1. Patient flow chart (DOCX 93 kb)
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Fig. 1 Kaplan–Meier curves for persistence for reasons other than disease progression: a dependent on adverse events within the first 30 days, b dependent
on noncompliance due to illness, c dependent on noncompliance in the past 30 days. a Kaplan-Meier curves for at least one adverse event within the first
30 days after therapy start (0 = no adverse event; 1 = any adverse event). b Kaplan-Meier curves for the question „Do you not take your medicine at all if you
feel worse due to illness?” (0 = False; 1 = True). c: Kaplan-Meier curves for the question „On how many days in the past 30 days did you not take/forget to
take your medicine?” (0 = 0 days; 1 = 1–10 days)
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